Nouveau Medicament Profile
Key Indicators
- Authorised Capital ₹ 4.10 Cr
as on 28-07-2024
- Paid Up Capital ₹ 1.48 Cr
as on 28-07-2024
- Company Age 23 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.62 M
as on 28-07-2024
- Revenue -9.62%
(FY 2023)
- Profit -65.95%
(FY 2023)
- Ebitda -36.07%
(FY 2023)
- Net Worth 3.82%
(FY 2023)
- Total Assets 1.58%
(FY 2023)
About Nouveau Medicament
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.10 Cr and a paid-up capital of Rs 1.48 Cr.
The company has closed loans amounting to ₹0.62 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Uma Iyer, Bhagyalakshmi Gowrishankar, Raamganesh Samakkulam, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24231TN2001PTC046971
- Company No.
046971
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Apr 2001
- Date of AGM
20 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nouveau Medicament Private Limited offer?
Nouveau Medicament Private Limited offers a wide range of products and services, including Health Conditions, Stomach Care, Heart Care, Piles, Fissures & Fistula, Women Care, Mother Care.
Who are the key members and board of directors at Nouveau Medicament?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karthikraman Samakulam  | Whole-Time Director | 02-Mar-2009 | Current |
| Uma Iyer | Whole-Time Director | 17-Apr-2001 | Current |
| Bhagyalakshmi Gowrishankar | Whole-Time Director | 23-Feb-2011 | Current |
| Raamganesh Samakkulam | Whole-Time Director | 02-Mar-2009 | Current |
| Ramanan Ramalingam | Whole-Time Director | 02-Mar-2009 | Current |
| Dhevarajan Ramalingam | Whole-Time Director | 02-Mar-2009 | Current |
Financial Performance of Nouveau Medicament.
Nouveau Medicament Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.62% decrease. The company also saw a substantial fall in profitability, with a 65.95% decrease in profit. The company's net worth moved up by a moderate rise of 3.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nouveau Medicament?
In 2023, Nouveau Medicament had a promoter holding of 91.39% and a public holding of 8.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 24 Sep 2004 | ₹0.62 M | Satisfied |
How Many Employees Work at Nouveau Medicament?
Nouveau Medicament has a workforce of 278 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nouveau Medicament, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nouveau Medicament's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
